Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Post by Thejew on Jul 12, 2019 3:45pm
102 Views
Post# 29915086

Clarity on RS

Clarity on RSLet me clear up some confusion here. For starters, if the RS is voted on, it does not mean it will even be implemented. It certainly would not be used anywhere near these prices, because it would be pointless. As the PR states, multiple times, it is a "just in case" scenario. And here is that scenario: They release positive data and other good news (licensing/partnership etc) and the PPS goes bonkers to .30ish. Now they have big pharma and institutions looking at them, but wont touch a penny stock and want them to uplist. Now they can do the RS and reach the minimum for lets say the NYSE ($4). They then can uplist and we all win and the negativity of the RS is thrown out the window because the stock is already up huge and were uplisting and then the big guys take us seriously. Again, if the RS passes, it does NOT mean it is even going to happen. They could keep diluting without an RS if they wanted to. I just think the timing sucks and is more ammo for the shorts, so I am voting against it. I hope that helps.
Bullboard Posts